Please assess the completion status of the following clinical trial:

Trial Title: A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years and ≤75 years old at Visit 1;~* Chinese patient with diagnosis of Type 2 diabetes prior to Visit 1;~* A stable treatment with premixed Insulin (≥ 20IU/day) or basal insulin (≥ 16 IU/day) for at least 12 weeks prior to enrolment with or without up to two OADs~  * With maximum insulin dose of ≤ 1 unit/kg/day. Acceptable basal insulins should have duration of action up to 24 h such as insulin Degludec, insulin glargin, insulin detemir or NPH (neutral protamine hagedorn) insulin; Acceptable pre-mixed insulins could be once or twice daily posology only. The total insulin dose should not be changed by more than 20% of the baseline value within the 12 weeks prior to randomisation (Visit 3). Both human insulin \& insulin analogue are acceptable;~ * If the patient is taking OADs, regimen has to be unchanged for at least 12 weeks prior to randomization (Visit 3);~ * If the patient is taking metformin, stable dose (at least 1500 mg daily or maximum tolerated dose) must be maintained for at least 12 weeks without dose adjustments prior to randomization (Visit 3);~* HbA1c ≥7.5% and ≤11.0% at Visit 1;~* Fasting C-peptide: \>0.5 ng/mL (\>166pmol/L) at Visit 1；~* 18.5 kg/m2 ≤ BMI ≤ 45 kg/m2 at Visit 1;~* Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial;~* Male or female patients. Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information.~Exclusion Criteria:~* Diagnosis of Type 1 diabetes;~* Patients receiving MDI insulin or insulin pump treatment;~* eGFR \<45ml/min/1.73m2 calculated based on MDRD formula;~* Uncontrolled hyperglycemia \[glucose level \>13. 9 mmol/l after an overnight fast during placebo run-in\];~* Severe hypoglycemia episode (event requiring the assistance of another person to actively administer carbohydrate, glucagon or other resuscitative actions) within 6 months prior to Visit 1;~* History of diabetic ketoacidosis or hyperosmolar non-ketotic coma. Myocardial infarction, stroke or transient ischaemic attack within 3 months prior to Visit 1;~* Bariatric surgery;~* Further criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Empagliflozin 10 mg (Type: EXPERIMENTAL): 1 table of 10 milligrams (mg) of Empagliflozin was administered orally once daily for a treatment period of 24 weeks.~Before the first dose of randomised drug, all participants went through a 2-week open label placebo run-in period, taking Placebo tablets orally once daily.
- Empagliflozin 25 mg (Type: EXPERIMENTAL): 1 table of 25 milligrams (mg) of Empagliflozin was administered orally once daily for a treatment period of 24 weeks.~Before the first dose of randomised drug, all participants went through a 2-week open label placebo run-in period, taking Placebo tablets orally once daily.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo was administered orally once daily for a treatment period of 24 weeks.~Before the first dose of randomised drug, all participants went through a 2-week open label placebo run-in period, taking Placebo tablets orally once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).